Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.73 |
| ▸ | CA2 | P00918 | 1/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA9 | Q16790 | 1/20 | 0.73 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.72 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.72 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.72 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.72 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.72 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.72 |
| ▸ | LDHA | P00338 | 1/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.72 |
| ▸ | FBP1 | P09467 | 1/20 | 0.72 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.72 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14201601 | 1.00 | CA1 (0.73) | CA1CA2CA4CA9P2RY1 | |
| SCHEMBL30208039 | 1.00 | CA1 (0.73) | CA1CA2CA4CA9P2RY1 | |
| SCHEMBL2294876 | 1.00 | CA1 (0.73) | CA1CA2CA4CA9P2RY1 | |
| SCHEMBL29754360 | 0.93 | TAS1R3 (0.75) | P2RY1ADORA1SMN1; SMN2P2RY2TAS1R3 | |
| SCHEMBL1066377 | 0.93 | TAS1R3 (0.75) | P2RY1ADORA1SMN1; SMN2P2RY2TAS1R3 | |
| SCHEMBL8954219 | 0.93 | TAS1R3 (0.75) | P2RY1ADORA1SMN1; SMN2P2RY2TAS1R3 | |
| SCHEMBL11459665 | 0.92 | ADORA1 (0.71) | P2RY1ADORA1SMN1; SMN2P2RY2TAS1R3 | |
| SCHEMBL35050 | 0.89 | ADORA1 (0.68) | P2RY1ADORA1SMN1; SMN2P2RY2TAS1R3 | |
| SCHEMBL4650247 | 0.89 | IARS1 (0.69) | P2RY1ADORA1SMN1; SMN2P2RY2TAS1R3 | |
| SCHEMBL1796966 | 0.88 | ATG7 (0.63) | CA1CA2CA4CA9P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109675-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-16 | — | — | US | disclosed |
| US-12496310-B2 | Compositions and methods for adoptive cell therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-12-16 | — | — | US | disclosed |
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-10-07 | — | — | US | disclosed |
| EP-3645561-B1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-05-07 | — | — | EP | disclosed |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-03-04 | — | — | US | disclosed |
| US-12178830-B2 | Compositions and methods for adoptive cell therapy for cancer | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-12-31 | — | — | US | disclosed |
| US-20240318134-A1 | IN VITRO GENERATION OF ORGANIZED 3D CELL STRUCTURES INCLUDING HEAD-TRUNK EMBRYO-LIKE STRUCTURES, USING EPIGENETIC REMODELING FACTORS-MICROFLUIDIC PLATFORM SUITABLE FOR THEIR GENERATION | ECOLE POLYTECHNIQUE (FR) | 2024-09-26 | — | — | US | disclosed |
| EP-4373916-A2 | IN VITRO GENERATION OF ORGANIZED 3D CELL STRUCTURES INCLUDING HEAD-TRUNK EMBRYO-LIKE STRUCTURES, USING EPIGENETIC REMODELING FACTORS - MICROFLUIDIC PLATFORM SUITABLE FOR THEIR GENERATION | INSTITUT PASTEUR (FR) | 2024-05-29 | — | — | EP | disclosed |
| EP-4219685-A1 | IN VITRO GENERATION OF ORGANIZED 3D CELL STRUCTURES INCLUDING HEAD-TRUNK EMBRYO-LIKE STRUCTURES, USING EPIGENETIC REMODELING FACTORS - MICROFLUIDIC PLATFORM SUITABLE FOR THEIR GENERATION | INSTITUT PASTEUR (FR) | 2023-08-02 | — | — | EP | disclosed |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| EP-1960518-A2 | ANTIBACTERIAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007067559-A2 | ANTIBACTERIAL AGENTS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-06-14 | — | — | WO | disclosed |
| WO-2006113615-A2 | ANTI-MICROBIAL AGENTS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-26 | — | — | WO | disclosed |
| US-4992426-A | Antiparasitic 5'-sulfamoyl nucleosides | NUCLEIC ACID RESEARCH INSTITUTE (US) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103696-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | CCRL2, CCR3, LY6K | CA1 257/4885CA2 117/4885CA4 194/4885 |
| US-12496310-B2 | Compositions and methods for adoptive cell therapy | HAVCR2, CD4, CCR1 | CA1 286/4885CA2 1038/4885CA4 488/4885 |
| US-20240318134-A1 | IN VITRO GENERATION OF ORGANIZED 3D CELL STRUCTURES INCLUDING HEAD-TRUNK EMBRYO-LIKE STRUCTURES, USING EPIGENETIC REMODELING FACTORS-MICROFLUIDIC PLATFORM SUITABLE FOR THEIR GENERATION | CHD3, EHMT1, EHMT2 | CA1 2147/4885CA2 3234/4885CA4 1386/4885 |
| US-12241097-B2 | Compositions and methods for adoptive cell therapy for cancer | CD2, PBK, CD4 | CA1 125/4885CA2 800/4885CA4 192/4885 |
| US-12435088-B2 | Salicyl-adenosinemonosulfamate analogs and uses thereof | ADSL, SLC35B2, ADORA1 | CA1 4660/4885CA2 3458/4885CA4 4278/4885 |
| US-20260109675-A1 | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER | IL2RA, CCR3, CD4 | CA1 106/4885CA2 76/4885CA4 135/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | CA1 4489/4885CA2 1905/4885CA4 3061/4885 |
| US-20090170805-A1 | ANTI-MICROBIAL AGENTS AND USES THEREOF | ACAT1, ACAT2, APEH | CA1 4226/4885CA2 2174/4885CA4 3206/4885 |
| US-12178830-B2 | Compositions and methods for adoptive cell therapy for cancer | CD2, PBK, CD4 | CA1 125/4885CA2 800/4885CA4 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.